PEG 3500 Market

• Rising prevalence of colon cancer in India and other developing nations boosts market growth

The prevalence of colon cancer is increasing across India and other developing nations. In countries such as India, China, and Japan cases of colon cancer is increasing at a high rate. For instance, according to the article published by, lancet regional health Southeast Asia, colorectal cancer is the 7th most common cancer in India with 65,358 new cases in 2021. The incidence of colon cancer has been increasing worldwide and is currently 19.5 per 100,000 population globally and 15.2 per 100,000 population in India.

Moreover, rise in the number of strategic initiatives in the form of mergers, acquisitions, product approval, collaborations, and partnerships in order to gain a competitive edge and offer advanced treatment options for occasional constipation. In April 2018, US Food and Drug Administration (FDA) approved Bayer AG (Germany) MiraLAX a PEG 3350 medication drug to treat occasional constipation. Hence, increasing prevalence of colon cancer in developing nations and rising initiative strategies are driving the market growth.

The Global PEG 3500 Market Industry experiences a notable surge in demand from the pharmaceutical sector. PEG 3500 serves as an excipient in various formulations, enhancing solubility and stability. As the global pharmaceutical market is projected to reach 1.96 USD Billion in 2024, the role of PEG 3500 becomes increasingly vital. The growing focus on drug delivery systems and the development of novel therapeutics further drive this demand. Additionally, regulatory approvals for PEG-based formulations contribute to market growth, indicating a robust future for PEG 3500 in pharmaceuticals.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America PEG 3500 market accounted for the largest market share in 2021, due to the rising prevalence of colorectal cancer and other diseases such as diabetes, cancer, and neurological disorders increases the demand for PEG 3500, driving the region's growth.

Further, the major countries studied are: The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: PEG 3500 MARKET BY REGION 2021 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe PEG 3500 market accounts for the second-largest market share owing to the increasing adoption of a sedentary lifestyle further increases the chance of colon cancer. Colorectal cancer is the most common form of cancer in Europe. As per the World Cancer Research Fund International, Hungary had the highest colorectal cancer number, followed by Slovakia in 2020 globally. Furthermore, the Germany PEG 3500 market held the largest market share 2021, and is projected to be the fastest growing during the forecast period.

The Asia-Pacific PEG 3500 market is expected to grow at a significant share from 2024 to 2032 rising geriatric population, adoption of sedentary lifestyles and physical inactivity, and the rising prevalence of colorectal cancer. The prevalence of constipation among the geriatric population is high and chronic. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four older people will be living in the Asia-Pacific region.

Moreover, China PEG 3500 market held the largest market share, and India PEG 3500 market is projected to be the fastest growing market in the Asia-Pacific region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the PEG 3500 market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the PEG 3500 industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Pendopharm (Canada) manufactures and distributes pharmaceutical products. The Company offers licensing, partnering, developing, and marketing specialty prescription medicines, as well as consumer healthcare products. Pendopharm serves customers in Canada. In March 2021, the company launched Colyte Polyethylene Glycol 3350 and Electrolytes for Oral Solution is used to cleanse the colon (bowel) before certain medical tests (e.g., colonoscopy, barium enema X-ray exam) or colon surgery.